These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 22563239)

  • 61. A randomized comparison of care provided by a clinical nurse specialist, an inpatient team, and a day patient team in rheumatoid arthritis.
    Tijhuis GJ; Zwinderman AH; Hazes JM; Van Den Hout WB; Breedveld FC; Vliet Vlieland TP
    Arthritis Rheum; 2002 Oct; 47(5):525-31. PubMed ID: 12382302
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders: 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY).
    Dougados M; Kissel K; Sheeran T; Tak PP; Conaghan PG; Mola EM; Schett G; Amital H; Navarro-Sarabia F; Hou A; Bernasconi C; Huizinga TW
    Ann Rheum Dis; 2013 Jan; 72(1):43-50. PubMed ID: 22562983
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Whole Blood Viscosity and Thromboembolic Events in Hospitalized Patients with COVID-19: Post hoc Analysis of the ATTACC/ACTIV-4a Trial.
    Choi D; Froess JD; Lawler PR; Neal MD; Zarychanski R; Rosenson RS;
    Thromb Haemost; 2024 Apr; ():. PubMed ID: 38684221
    [No Abstract]   [Full Text] [Related]  

  • 64. Learning From the Success of the ACTIV Platform.
    Ross JS; Malani P
    JAMA; 2023 Dec; 330(24):2363-2364. PubMed ID: 37976051
    [No Abstract]   [Full Text] [Related]  

  • 65. Patient Preferences for Time and Location of Infusible Therapies in Multiple Sclerosis and Neuroimmunologic Disorders.
    Rath L; Campagna MP; Stankovich J; Ellis J; Jokubaitis V; McCarthy D; Nesbitt C; Yeh WZ; Zhong M; Wesselingh R; Monif M; Richards J; Minh VB; Skibina O; Butzkueven H; van der Walt A
    Int J MS Care; 2021; 23(3):114-118. PubMed ID: 34177383
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Patient preferences and satisfaction in a multispecialty infusion center.
    Ostrov BE; Reynolds K; Scalzi LV
    Patient Prefer Adherence; 2014; 8():755-61. PubMed ID: 24876769
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Tocilizumab: a review of its use in the management of rheumatoid arthritis.
    Oldfield V; Dhillon S; Plosker GL
    Drugs; 2009; 69(5):609-32. PubMed ID: 19368420
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Survey of a community-based infusion program for Australian patients with rheumatoid arthritis requiring treatment with tocilizumab: patient characteristics and drivers of patient satisfaction and patient-perceived benefits and concerns.
    Voight L
    Patient Prefer Adherence; 2012; 6():275-83. PubMed ID: 22563239
    [TBL] [Abstract][Full Text] [Related]  

  • 69. [The efficacy and safety of tocilizumab combined with disease-modifying anti-rheumatoid drugs in the treatment of active rheumatoid arthritis: a multi-center, randomized, double-blinded, placebo-controlled trial].
    Shi Q; Zhao Y; Bao CD; Li XF; Huang F; Zhu P; Li ZG; Gu JR; Zhang ZY; Zhao DB; Zhao SL; Jiang QD; Tian J; Zhang FC
    Zhonghua Nei Ke Za Zhi; 2013 Apr; 52(4):323-9. PubMed ID: 23925361
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Group cognitive-behavioural programme to reduce the impact of rheumatoid arthritis fatigue: the RAFT RCT with economic and qualitative evaluations.
    Hewlett S; Almeida C; Ambler N; Blair PS; Choy E; Dures E; Hammond A; Hollingworth W; Kadir B; Kirwan J; Plummer Z; Rooke C; Thorn J; Turner N; Pollock J
    Health Technol Assess; 2019 Oct; 23(57):1-130. PubMed ID: 31601357
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Patient satisfaction and clinical effectiveness of switching from intravenous tocilizumab to subcutaneous tocilizumab in patients with juvenile idiopathic arthritis: an observational study.
    Ayaz NA; Karadağ ŞG; Koç R; Demirkan FG; Çakmak F; Sönmez HE
    Rheumatol Int; 2020 Jul; 40(7):1111-1116. PubMed ID: 32417938
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Efficacy and safety profile of intravenous tocilizumab versus intravenous abatacept in treating female Saudi Arabian patients with active moderate-to-severe rheumatoid arthritis.
    Elmedany SH; Mohamed AE; Galil SMA
    Clin Rheumatol; 2019 Aug; 38(8):2109-2117. PubMed ID: 30915650
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Rheumatoid arthritis: bringing care closer to home.
    Phillips J
    Br J Community Nurs; 2011 Jul; 16(7):340. PubMed ID: 21727792
    [No Abstract]   [Full Text] [Related]  

  • 74. Understanding emerging treatment paradigms in rheumatoid arthritis.
    Breedveld FC; Combe B
    Arthritis Res Ther; 2011 May; 13 Suppl 1(Suppl 1):S3. PubMed ID: 21624182
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Efficacy of abatacept and tocilizumab in patients with rheumatoid arthritis treated in clinical practice: results from the nationwide Danish DANBIO registry.
    Leffers HC; Ostergaard M; Glintborg B; Krogh NS; Foged H; Tarp U; Lorenzen T; Hansen A; Hansen MS; Jacobsen MS; Dreyer L; Hetland ML;
    Ann Rheum Dis; 2011 Jul; 70(7):1216-22. PubMed ID: 21551512
    [TBL] [Abstract][Full Text] [Related]  

  • 76.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 77.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 78.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 79.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 80.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.